Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.


Results 291 - 300 of 333

<< Previous | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | Next >>

Last updated: 20th February 2008

Patent No.: WO 9800023
Induction of plant resistance to pathogens by a jasmonate pathway and the characterization of jasmonate-responsive genes.
Applicant: Broekaert WF, Thomma BPHJ, Penninckx IAMA, Terras FRG, Manners JM, Kazan K (1998)
A method of protecting a plant against pathogens by inducing expression of a plant defensin gene by stimulating the jasmonate and/or ethylene pathways is described. Signal transduction chains involved in the induction of the response to jasmonate are also characterized. The jasmonate pathway interacts synergistically with the ethylene pathway. Reporter gene methods for screening for inducers of defensin genes are also described. Preferably, the pathogen is a necrotrophic pathogen.

Patent No.: WO 9842365
Hormone/lytic peptides and therapeutic use in controlling cancer, viral infection, and autoimmune diseases and in inducing sterility.
Applicant: Enright FM, Jaynes JM, Hansel W, Koonce KL, McCann SM, Yu WH, Melrose PA, Foil LD, Elzer PH (1998)
Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compds. are relatively small, and are not antigenic. Lysis of gonadotropes has been obsd. to be very rapid (on the order of ten minutes). Lysis of tumor cells is rapid. The two components -the ligand and the lytic peptide- may optionally be administered as a fusion peptide, or they may be administered sep., with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide. The compds. may be used in gene therapy to treat malignant or non-malignant tumors, and other diseases caused by clones or populations of "normal" host cells bearing specific receptors (such as lymphocytes), because genes encoding a lytic peptide or encoding a lytic peptide/peptide hormone fusion may readily be inserted into hematopoietic stem cells or myeloid precursor cells. The lytic peptide tested was hecate, a synthetic peptide analog of melittin.

Patent No.: WO 9840502
Increasing the efficiency of uptake of transforming DNA complexes with polycations using peptides.
Applicant: Hawley-Nelson P, Lan J, Shih P, Jessee JA, Ciccarone VC, Evans KL, Schifferli KP, Gebeyehu G (1998)
The present invention provides compositions useful for transfecting eukaryotic cells, comprising nucleic acid complexes with peptides, wherein the peptide is optionally covalently coupled to a nucleic acid-binding group, and cationic lipids or dendrimers as transfection agents. The invention also provides transfection compositions in which a peptide is covalently linked to the transfection agent (lipid, cationic lipid or dendrimer). The peptides may be synthetic or derived from a cellular protein and may be further derivatized, e.g. by selective deprotection. Inclusion of peptides or modified-peptides in transfection compns. or covalent attachment of peptides to transfection agents increases transfection efficiency. Methods for the prepn. of such transfection compns. and methods of using these transfection compns. as intracellular delivery agents and extracellular targeting agents are disclosed. It is suggested that defensin peptides can be used in these transfection compositions because 1) the defensins' cationicity assists in their binding the transfectant nucleic acids, and 2) defensins have membrane-perturbing action.

Patent No.: WO 9838205
Positive-selection vectors using genes for restriction enzymes as the selectable marker and cloning site.
Applicant: Rashtchian A, Chatterjee D, Guan N, Schuster D (1998)
Nucleic acid molecules are disclosed which comprise a toxic gene operably linked to a regulatory DNA sequence, wherein the regulatory DNA sequence contains one or more cloning sites allowing insertional inactivation of the toxic gene. Also disclosed are kits for cloning and selecting a gene which comprise the nucleic acid molecules of the invention. Also disclosed are methods of cloning and selecting nucleic acid molecules in a transformed host cell using the methods and compositions of the invention. In the practice of the invention, when a genetic insert is inserted into a cloning site within the nucleic acid molecule comprising the toxic gene, the toxic gene is rendered substantially non-toxic to the host cell, allowing for the isolation of viable transformants which comprise the gene to be cloned and selected. The invention also provides stable compositions for cloning and selecting a nucleic acid molecule, vectors and host cells comprising these nucleic acid molecules, kits for cloning and selecting a nucleic acid molecule, methods for producing recombinant polypeptides using these nucleic acid molecules and compositions, and recombinant polypeptides produced according to these methods.

Patent No.: WO 9807833
Compositions and methods for use of defensin.
Applicant: Wilson JM, Goldman M, Bals R, Stolzenberg ED, Anderson M, Zasloff M, Kari P (1998)
The invention relates to mammalian beta defensin and methods of use thereof for treatment of microbial infection.

Patent No.: WO 9806419
Enhancement of antimicrobial peptide activity by metal ions.
Applicant: Lawyer CH, Watabe K (1998)
Provided are methods for maintaining or enhancing the antimicrobial activity of antimicrobial peptides, lytic peptides, and peptide-derived antibiotics by the use of metal ions. Also provided are pharmaceutical and other compns. comprising such peptides and/or at least one metal ion. Also provided are therapeutic and other methods for controlling the growth of undesirable or pathogenic microorganisms in various loci or milieu in, on, or outside the body employing these peptides and metal ions. Also provided are kits comprising containers contg. a peptide and a metal ion(s), resp.

Patent No.: US 6172185
Antimicrobial cationic peptide derivatives of bactenecin.
Applicant: Hancock REW, Wu M (1998)
A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include RLARIVVIRVAR (SEQ ID NO:2) and RLSRIVVIRVCR (SEQ ID NO:3). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention.

Patent No.: US 5844072
Antibiotic cryptdin peptides and methods of their use.
Applicant: Selsted ME, Ouellette AJ (1998)
The present invention provides substantially purified cryptdin peptides having a consensus amino acid sequence: X.sub.1 -C-X.sub.2 -C-R-X.sub.3 -C-X.sub.4 -E-X.sub.5 -C-X.sub.6 -C-C-X.sub.7 or having a consensus amino acid sequence: X.sub.1 -L-X.sub.2 -C-Y-C-R-X.sub.3 -C-K-X.sub.4 -E-X.sub.5 -G-T-C-X.sub.6 -C-C-X.sub.7 wherein X.sub.1 to X.sub.7 each independently is 0 to 10 amino acids. The invention also provides cryptdin analogs, which are devoid of one or more amino acids N-terminal to the first cysteine. In addition, the invention provides nucleic acid molecules encoding cryptdin peptides. The invention further provides methods for detecting inflammatory pathologies in a subject and for treating an inflammatory pathology in a subject by administering a pharmaceutical composition containing a cryptdin peptide.

Patent No.: US 5843426
Salmonella vaccines.
Applicant: Miller SI, Mekalanos JJ (1998)
The invention features a Salmonella cell the virulence of which is attenuated by a deletion of a portion of the PhoQ gene and Salmonella cells having a deletion of the PhoQ gene and a deletion of the PhoP gene. The invention also features vaccines comprising such bacteria.

Patent No.: US 5837247
Defensins as chemotactic agents for T cells.
Applicant: Oppenhelm JJ, Michiel D, Chertov O, Taub DD, Xu L, Wang JM, Murphy WJ (1998)
Chemotactic activity of defensins and CAP37 is disclosed. Methods of treatment assocd. with such activity and compns. for such treatment are also provided.